Corcept Therapeutics, Inc.

How big is Corcept Therapeutics, Inc.?

As of Jun 18, Corcept Therapeutics, Inc. has a market capitalization of $8.04 billion, with net sales of $685.45 million and a net profit of $132.49 million over the last four quarters.

Market Cap: As of Jun 18, Corcept Therapeutics, Inc. has a market capitalization of 8,039.71 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Corcept Therapeutics, Inc. reported net sales of 685.45 million and a net profit of 132.49 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 679.59 million and total assets of 840.55 million.

What does Corcept Therapeutics, Inc. do?

Corcept Therapeutics, Inc. is a pharmaceutical company focused on developing drugs for severe metabolic, psychiatric, and oncologic disorders. As of March 2025, it reported net sales of $157 million and a net profit of $20 million, with a market cap of approximately $8.04 billion.

Overview:<BR>Corcept Therapeutics, Inc. is a pharmaceutical company engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 157 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 20 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 8,039.71 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 59.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.47 <BR>Return on Equity: 19.39% <BR>Price to Book: 11.77<BR><BR>Contact Details:<BR>Address: 149 Commonwealth Dr, MENLO PARK CA 94025-1133 <BR>Tel: 1 650 3273270 <BR>Fax: 1 650 3273218 <BR>Website: http://www.corcept.com/

Should I buy, sell or hold Corcept Therapeutics, Inc.?

Who are in the management team of Corcept Therapeutics, Inc.?

As of March 2022, the management team of Corcept Therapeutics, Inc. includes Mr. James Wilson (Independent Chairman), Dr. Joseph Belanoff (CEO), Dr. Gillian Cannon, and several independent directors: Mr. Gregg Alton, Mr. George Baker, Mr. David Mahoney, and Ms. Kimberly Park. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Corcept Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. James Wilson, Independent Chairman of the Board<BR>- Dr. Joseph Belanoff, President, Chief Executive Officer, and Director<BR>- Dr. Gillian Cannon, Director<BR>- Mr. Gregg Alton, Independent Director<BR>- Mr. George Baker, Independent Director<BR>- Mr. David Mahoney, Independent Director<BR>- Ms. Kimberly Park, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Corcept Therapeutics, Inc. overvalued or undervalued?

As of August 4, 2025, Corcept Therapeutics, Inc. is considered very expensive due to high valuation ratios, including a P/E of 59 and an EV to EBITDA of 66.34, despite strong stock performance that significantly outpaced the S&P 500.

As of 4 August 2025, the valuation grade for Corcept Therapeutics, Inc. moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is overvalued based on its high valuation ratios, including a P/E ratio of 59, an EV to EBITDA of 66.34, and a PEG ratio of 5.37. In comparison, peers such as ACADIA Pharmaceuticals, Inc. have a P/E of 19.28 and an EV to EBITDA of 33.99, highlighting the premium at which Corcept is trading.<BR><BR>Additionally, Corcept's recent stock performance has outpaced the S&P 500, with a year-to-date return of 58.36% compared to the index's 12.22%, and a one-year return of 88.79% versus 17.14%. This strong performance may reflect investor enthusiasm, but the elevated valuation ratios suggest that the stock may not be justified at its current price.

Is Corcept Therapeutics, Inc. technically bullish or bearish?

As of October 10, 2025, Corcept Therapeutics, Inc. shows a mildly bullish technical trend, with a year-to-date return of 41.95% significantly outperforming the S&P 500's 11.41%, despite a recent short-term decline of 20.39%.

As of 10 October 2025, the technical trend for Corcept Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish. Both the weekly and monthly Bollinger Bands indicate a mildly bullish stance, and moving averages on the daily chart also reflect a mildly bullish trend. The KST and Dow Theory are bullish on the weekly and monthly time frames, while the OBV shows a mildly bullish trend. <BR><BR>In terms of performance, Corcept has outperformed the S&P 500 significantly over the longer term, with a year-to-date return of 41.95% compared to the S&P 500's 11.41%, and a 3-year return of 155.74% versus 81.39% for the index. However, in the short term, the stock has declined by 20.39% over the past week, while the S&P 500 fell only 2.43%. Overall, the current technical stance is mildly bullish.